FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* INGENITO GARY				<u>C.</u>	2. Issuer Name and Ticker or Trading Symbol CATALYST PHARMACEUTICALS, INC. CPRX						<u></u> (Ch	5. Relationship of Reporting Person( (Check all applicable) Director  Officer (give title				ner	
(Last) (First) (Middle) 355 ALHAMBRA CIRCLE, SUITE 801				3.1	3. Date of Earliest Transaction (Month/Day/Year) 02/14/2022							below)			Other (sp below) Officer	, l	
(Street) CORAL GABLES			33134	4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicatine)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(City)	(St		(Zip) le I - Non-De	rivativ		curities	. Δc	nuired D	ieno	n hazı	of or Re	neficial	v Owner	<u> </u>			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				ansaction	2A. Deemed Execution Date,		3. 4. Securiti Transaction Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 a		5. Amou Securitie Beneficie Owned F	nt of es ally following	6. Owner Form: Di (D) or Inc (I) (Instr.	rect o direct B 4) C	7. Nature of Indirect Beneficial Ownership		
							Code V	Aı	Mount	(A) or (D)	Price	Reported Transact (Instr. 3	ion(s)		(1	(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		e and	7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y Ow Fo Dir or (I)	vnership rm: rect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expi Date	iration e	Title	Amount or Number of Shares					
Restricted Stock Units	(1)	02/14/2022		A		30,000		(2)	(	(3)	Common Stock	30,000	\$0	1,221,66	57	D	

## **Explanation of Responses:**

- 1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
- $2.\ Derivative\ securities\ vest\ in\ equal\ tranches,\ 1/3rd\ on\ February\ 14,\ 2023,\ 1/3rd\ on\ February\ 14,\ 2024\ and\ 1/3rd\ on\ February\ 14,\ 2025.$
- $3. \ Shares \ of \ common \ stock \ will \ be \ delivered \ to \ the \ Reporting \ Person \ within \ sixty \ (60) \ days \ of \ vesting.$

/s/ Gary Ingenito

02/16/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.